Clinical Trial

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Protocol Amendment History 3 changes
notable Trial sites reduced: 47 -> 40 locations 2026-05-08
notable Trial sites expanded: 42 -> 47 locations 2026-05-05
notable Trial sites expanded: 37 -> 42 locations 2026-04-15
Trial Details
NCT Number NCT07124078
Lead Sponsor Incyte Corporation
Conditions Chronic Graft-versus-host-disease
Enrollment 60 participants
Start Date 2026-05-20
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02